December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-002854-21/ Novartis Protocol ID CNVA237A2311

A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/fluticasone propionate in COPD patients with moderate to severe airflow limitation

Trial CNVA237A2311 was cancelled with no patient enrollment and as such, no results will be reported.